Gene synthesis/DNA custom sequencing integrated DNA technologies INC:1107504 [17-004880]
Ended Awarded Last action
- Contract number
- HHSN26400006
- Awardee
-
Integrated DNA Technologies, Inc. UEI P55FTN1UMYZ1
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,755
Award facts
- Contract value 100% obligated
- $11,754.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325199 All Other Basic Organic Chemical Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Coralville, IA 52241, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $11,755 |
About this award
Integrated DNA Technologies, Inc. (IDT), a leading manufacturer of specialized nucleic acid products headquartered in Coralville, Iowa, received a Blanket Purchase Agreement (BPA) call award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for gene synthesis and DNA custom sequencing services. The contract, valued at $11,754.88, was awarded on August 22, 2017, with an ultimate completion date of August 23, 2018, under firm fixed-price terms. This BPA call represents a task order against an existing IDT blanket purchase agreement vehicle with the federal government, enabling the procurement of specialized molecular biology products and services to support the agency's research initiatives.
The award carries no set-aside designation, reflecting IDT's competitive position in the open market for federal research procurement. As a parent corporate entity registered with the System for Award Management (SAM) since 2001, IDT has established itself as a key supplier to multiple federal agencies including the National Institutes of Health, Centers for Disease Control and Prevention, and the Department of Defense. The company's specialization in custom DNA and RNA oligonucleotides, gene fragments, sequencing products, and related molecular biology reagents directly supports NIAMS's research mission in arthritis, musculoskeletal diseases, and skin disorders, where advanced genomic tools are essential for understanding disease mechanisms and developing therapeutic interventions.
Quick answers
Who was awarded contract HHSN26400006?
HHSN26400006 was awarded to Integrated DNA Technologies, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on August 22, 2017.
How much is contract HHSN26400006 worth?
The government has obligated $11,755 on HHSN26400006.
Is contract HHSN26400006 an order under another contract?
Yes. HHSN26400006 is a BPA call under HHSN263201500214B, a blanket purchase agreement.
Was contract HHSN26400006 competed?
The extent of competition for HHSN26400006 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award